219 related articles for article (PubMed ID: 27632196)
21. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
22. Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma.
Zheng J; Huang S; Huang Y; Song L; Yin Y; Kong W; Chen X; Ouyang X
Tumour Biol; 2016 Jun; 37(6):7853-9. PubMed ID: 26695153
[TBL] [Abstract][Full Text] [Related]
23. Combining CRP and CA19-9 in a novel prognostic score in pancreatic ductal adenocarcinoma.
Nurmi AM; Mustonen HK; Stenman UH; Seppänen HE; Haglund CH
Sci Rep; 2021 Jan; 11(1):781. PubMed ID: 33437015
[TBL] [Abstract][Full Text] [Related]
24. Clinical Implications of NRAS Overexpression in Resectable Pancreatic Adenocarcinoma Patients.
Martinez-Useros J; Li W; Georgiev-Hristov T; Fernandez-Aceñero MJ; Borrero-Palacios A; Perez N; Celdran A; Garcia-Foncillas J
Pathol Oncol Res; 2019 Jan; 25(1):269-278. PubMed ID: 29101736
[TBL] [Abstract][Full Text] [Related]
25. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
26. High JAK2 Protein Expression Predicts a Poor Prognosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma.
Song Y; Tang MY; Chen W; Wang Z; Wang SL
Dis Markers; 2020; 2020():7656031. PubMed ID: 33029256
[TBL] [Abstract][Full Text] [Related]
27. PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8
Yamaki S; Yanagimoto H; Tsuta K; Ryota H; Kon M
Int J Clin Oncol; 2017 Aug; 22(4):726-733. PubMed ID: 28314962
[TBL] [Abstract][Full Text] [Related]
28. Elevated preoperative plasma D-dimer level was an independent prognostic factor for patients with PDAC after curative resection: a retrospective analysis.
Zhifei L; Yuexiang L; Shaofei C; Shuo L; Hongwei W; Chuntao G
Jpn J Clin Oncol; 2023 Nov; 53(11):1058-1067. PubMed ID: 37539583
[TBL] [Abstract][Full Text] [Related]
29. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
Sun B; Liu X; Gao Y; Li L; Dong Z
Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
[TBL] [Abstract][Full Text] [Related]
30. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
31. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
[TBL] [Abstract][Full Text] [Related]
32. Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis.
de Rooij T; Tol JA; van Eijck CH; Boerma D; Bonsing BA; Bosscha K; van Dam RM; Dijkgraaf MG; Gerhards MF; van Goor H; van der Harst E; de Hingh IH; Kazemier G; Klaase JM; Molenaar IQ; Patijn GA; van Santvoort HC; Scheepers JJ; van der Schelling GP; Sieders E; Busch OR; Besselink MG;
Ann Surg Oncol; 2016 Feb; 23(2):585-91. PubMed ID: 26508153
[TBL] [Abstract][Full Text] [Related]
33. Prognostic impact of Ki-67 proliferative index in resectable pancreatic ductal adenocarcinoma.
Pergolini I; Crippa S; Pagnanelli M; Belfiori G; Pucci A; Partelli S; Rubini C; Castelli P; Zamboni G; Falconi M
BJS Open; 2019 Oct; 3(5):646-655. PubMed ID: 31592095
[TBL] [Abstract][Full Text] [Related]
34. High expression of delta-like ligand 4 predicts poor prognosis after curative resection for pancreatic cancer.
Chen HT; Cai QC; Zheng JM; Man XH; Jiang H; Song B; Jin G; Zhu W; Li ZS
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S464-74. PubMed ID: 21822553
[TBL] [Abstract][Full Text] [Related]
35. Comparison of ILK and ERP29 expressions in benign and malignant pancreatic lesions and their clinicopathological significances in pancreatic ductal adenocarcinomas.
Zhang K; Yao H; Yang Z; Li D; Yang L; Zou Q; Yuan Y; Miao X
Clin Transl Oncol; 2016 Apr; 18(4):352-9. PubMed ID: 26887611
[TBL] [Abstract][Full Text] [Related]
36. UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept.
Martinez-Useros J; Georgiev-Hristov T; Fernández-Aceñero MJ; Borrero-Palacios A; Indacochea A; Guerrero S; Li W; Cebrián A; Gómez Del Pulgar T; Puime-Otin A; Del Puerto-Nevado L; Rodríguez-Remírez M; Pérez N; Celdrán A; Gebauer F; Garcia-Foncillas J
PLoS One; 2017; 12(8):e0182044. PubMed ID: 28763470
[TBL] [Abstract][Full Text] [Related]
37. Pre-operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Resection.
Karasek P; Gablo N; Hlavsa J; Kiss I; Vychytilova-Faltejskova P; Hermanova M; Kala Z; Slaby O; Prochazka V
Cancer Genomics Proteomics; 2018; 15(4):321-327. PubMed ID: 29976637
[TBL] [Abstract][Full Text] [Related]
38. Role of the lymph node ratio in pancreatic ductal adenocarcinoma. Impact on patient stratification and prognosis.
La Torre M; Cavallini M; Ramacciato G; Cosenza G; Rossi Del Monte S; Nigri G; Ferri M; Mercantini P; Ziparo V
J Surg Oncol; 2011 Nov; 104(6):629-33. PubMed ID: 21713779
[TBL] [Abstract][Full Text] [Related]
39. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy.
Roland CL; Katz MH; Tzeng CW; Lin H; Varadhachary GR; Shroff R; Javle M; Fogelman D; Wolff RA; Vauthey JN; Crane CH; Lee JE; Fleming JB
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S1221-8. PubMed ID: 26350371
[TBL] [Abstract][Full Text] [Related]
40. Tumour budding in pancreatic cancer revisited: validation of the ITBCC scoring system.
Karamitopoulou E; Wartenberg M; Zlobec I; Cibin S; Worni M; Gloor B; Lugli A
Histopathology; 2018 Jul; 73(1):137-146. PubMed ID: 29495092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
